GLP-1s and Testosterone in Men: What Weight Loss Does to Low T

For men whose low testosterone is tied to excess weight, losing weight tends to raise testosterone, and the early studies of GLP-1 drugs fit that pattern. Several small studies and two recent reviews report that total testosterone goes up in men with obesity who take a GLP-1 receptor agonist or tirzepatide. What these studies can't yet tell us is whether the drug does anything beyond the weight loss itself, how durable the change is, or whether it improves symptoms in a meaningful way for most men.

None of this makes a GLP-1 a testosterone treatment. No GLP-1 medication is FDA-approved for low testosterone, and the research is a long way from the kind of large randomized trials that would change that.

How obesity lowers testosterone

Low testosterone in men falls into two broad groups. In one, something is structurally wrong with the testes or the pituitary gland, and the problem doesn't go away on its own. In the other, often called functional hypogonadism, the hormone system is intact but suppressed by something else, and obesity is one of the most common causes.

A 2013 systematic review in the European Journal of Endocrinology described this as obesity-associated hypogonadotropic hypogonadism, meaning the brain's signals to the testes are turned down. Its title makes the central point: body weight loss reverses it, at least in many men.

Fat tissue is hormonally active, and higher body fat is associated with changes in estrogen, insulin resistance, and the signaling hormones that drive testosterone production. The 2013 review found that weight loss lowered estradiol and raised gonadotropins (the pituitary hormones that stimulate the testes), which is consistent with this mechanism.

What weight loss alone does to testosterone

Before GLP-1 drugs became widely used for weight management, the best evidence came from diets and bariatric surgery. The 2013 meta-analysis pooled 24 studies and found:

• Both low-calorie diets and bariatric surgery significantly raised total testosterone.
• Surgery, which produced more weight loss, raised testosterone more than diet did.
• The amount of weight lost was the strongest predictor of how much testosterone rose.
• The effect was largest in younger men, men without diabetes, and men with more severe obesity.

That dose-response pattern is the most useful thing to understand going in. If GLP-1s raise testosterone, the simplest explanation is that they produce a lot of weight loss, and weight loss raises testosterone.

What the GLP-1 studies show

Three recent reviews are worth knowing about, each with different strengths:

For a sense of scale, 2.5 to 5.2 nmol/L is roughly 70 to 150 ng/dL, the units most U.S. labs use. That's a meaningful shift for a man sitting just under the normal range. It may not be enough for someone who starts much lower, and an average across studies says nothing about how any one man will respond.

How to read this evidence

• Small numbers. The largest meta-analysis covers 680 men across seven studies. That's useful but thin compared with the tens of thousands enrolled in GLP-1 weight-loss trials.
• Mostly lab values. The main outcome in most studies is a testosterone number. Fewer measured symptoms like energy, libido, or erectile function, and those are what matter to most men.
• Probably indirect. Both 2025 and 2026 reviews point to weight loss and improved insulin resistance as the likely drivers. The 2025 authors were explicit that current human data can't show a direct effect on the testes.
• Not a comparison with TRT. These studies don't show GLP-1s are as good as or better than testosterone therapy for men who need it. The network meta-analysis found no single approach clearly superior.

Why low T needs a real diagnosis first

Testosterone levels vary through the day and drop with acute illness and poor sleep. A single low result doesn't establish a diagnosis. The Endocrine Society's testosterone therapy guideline recommends diagnosing hypogonadism only in men who have symptoms and signs of deficiency along with consistently low testosterone, using a morning fasting total testosterone and confirming it with a repeat morning fasting test. If total testosterone is near the low end, or if a condition affects sex hormone-binding globulin, the guideline recommends checking free testosterone with an accurate method. Obesity is one of the conditions that can lower that binding protein.

The guideline also recommends finding the cause once low testosterone is confirmed. That matters here: if obesity is the main driver, weight loss is a reasonable part of the plan; if there's a pituitary or testicular cause, weight loss won't fix it.

Where testosterone therapy fits

This isn't an article for or against testosterone replacement therapy. For men with confirmed hypogonadism and symptoms, TRT is an established treatment that a clinician may recommend. It also has limits. The Endocrine Society guideline advises against starting it in several groups, including men who are planning to have children soon, because external testosterone can suppress sperm production. Other groups it lists include men with certain prostate or breast cancer findings, a high hematocrit, untreated severe sleep apnea, uncontrolled heart failure, or a heart attack or stroke in the past six months.

The guideline also recommends against using testosterone to improve blood sugar control in men with type 2 diabetes.

If you're already on TRT and start a GLP-1, don't stop or change your testosterone on your own. Your clinician may want to recheck levels as your weight changes, but that's a decision to make together.

Other factors that can move testosterone on a GLP-1

Weight loss isn't the only thing that changes when you start one of these drugs. A few other factors can push testosterone up or down, and they're worth mentioning to your clinician:

• Sleep apnea. The Endocrine Society guideline lists untreated severe sleep apnea as a reason not to start testosterone therapy, so it's worth knowing whether you have it. Zepbound is FDA-approved to treat moderate to severe sleep apnea in adults with obesity; see our sleep apnea guide.
• Very low intake. If appetite suppression has you barely eating, tell your prescriber. Very low intake is bad for muscle and overall nutrition, and it makes lab results harder to interpret.
• Muscle loss. Rapid weight loss includes some lean mass. Resistance training and adequate protein help, and our guide to protecting muscle on a GLP-1 covers the details.
• Other medications. Bring a full medication list. Your clinician can tell you whether anything you take could affect hormone levels or test results.

What to ask your clinician

1. Should we check testosterone before I start? If you have symptoms such as low libido, erectile problems, or persistent fatigue, a baseline morning fasting level gives you something to compare later. Our GLP-1 lab panel guide covers other baseline tests.
2. If it's low, what's the cause? Ask whether your clinician thinks it's mainly weight-related or whether other causes need ruling out.
3. When should we recheck? If weight is a driver, a recheck after meaningful weight loss can show whether levels have recovered.
4. What are my options if it doesn't improve? That's the point to discuss whether testosterone therapy or another treatment makes sense, and what monitoring it would need.
5. Am I planning to have children? Bring this up early. It affects which options are appropriate.

For other areas of early research on these drugs, see GLP-1s beyond weight loss.